受强制性开放获取政策约束的文章 - Alexey V Danilov了解详情
无法在其他位置公开访问的文章：7 篇
Cardiac non‐Hodgkin's lymphoma: clinical characteristics and trends in survival
MJ Gordon, O Danilova, S Spurgeon, AV Danilov
European journal of haematology 97 (5), 445-452, 2016
强制性开放获取政策： Lymphoma Research Foundation, USA
A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53
P Shindiapina, JR Brown, AV Danilov
British journal of haematology 167 (2), 149-161, 2014
强制性开放获取政策： Lymphoma Research Foundation, USA
Optimizing platelet GPVI inhibition versus haemostatic impairment by the Btk inhibitors ibrutinib, acalabrutinib, ONO/GS-4059, BGB-3111 and evobrutinib
V Denzinger, K Busygina, J Jamasbi, I Pekrul, M Spannagl, C Weber, ...
Thrombosis and Haemostasis 119 (03), 397-406, 2019
强制性开放获取政策： German Research Foundation
Targeting neddylation effectively antagonizes nuclear factor-κB in chronic lymphocytic leukemia B-cells
JC Godbersen, C Paiva, OV Danilova, A Berger, JR Brown, AV Danilov
Leukemia & lymphoma 56 (5), 1566-1569, 2015
强制性开放获取政策： Lymphoma Research Foundation, USA
Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities–is there an optimal dose?
MJ Gordon, LD Lewis, JR Brown, AV Danilov
Expert Review of Hematology 10 (8), 707-718, 2017
强制性开放获取政策： Lymphoma Research Foundation, USA
Role for ZAP-70 signaling in the differential effector functions of rituximab and obinutuzumab (GA101) in chronic lymphocytic leukemia B cells
S Skopelja-Gardner, JD Jones, BJN Hamilton, AV Danilov, WFC Rigby
The Journal of Immunology 199 (4), 1275-1282, 2017
强制性开放获取政策： US National Institutes of Health, Lymphoma Research Foundation, USA
S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL.
JE Amengual, P Reagan, H Li, H Saeed, R Vaidya, JM Unger, A Danilov, ...
Hematological Oncology 41, 2023
强制性开放获取政策： US National Institutes of Health
可在其他位置公开访问的文章：95 篇
Functional genomic landscape of acute myeloid leukaemia
JW Tyner, CE Tognon, D Bottomly, B Wilmot, SE Kurtz, SL Savage, ...
Nature 562 (7728), 526-531, 2018
强制性开放获取政策： US National Institutes of Health, Howard Hughes Medical Institute, V …
The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells
T Nechiporuk, SE Kurtz, O Nikolova, T Liu, CL Jones, A D'Alessandro, ...
Cancer discovery 9 (7), 910-925, 2019
强制性开放获取政策： US National Institutes of Health, Howard Hughes Medical Institute, V …
Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies
JJ Shatzel, SR Olson, DL Tao, OJT McCarty, AV Danilov, TG DeLoughery
Journal of thrombosis and haemostasis 15 (5), 835-847, 2017
强制性开放获取政策： US National Institutes of Health, Lymphoma Research Foundation, USA
Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data
D Sun, X Guan, AE Moran, LY Wu, DZ Qian, P Schedin, MS Dai, ...
Nature biotechnology 40 (4), 527-538, 2022
强制性开放获取政策： US Department of Defense, US National Institutes of Health
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
D Bottomly, N Long, AR Schultz, SE Kurtz, CE Tognon, K Johnson, M Abel, ...
Cancer cell 40 (8), 850-864. e9, 2022
强制性开放获取政策： US National Institutes of Health, Howard Hughes Medical Institute, V …
The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells
JC Godbersen, LA Humphries, OV Danilova, PE Kebbekus, JR Brown, ...
Clinical cancer research 20 (6), 1576-1589, 2014
强制性开放获取政策： US National Institutes of Health
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers
AM Evens, A Danilov, D Jagadeesh, A Sperling, SH Kim, R Vaca, C Wei, ...
Blood, The Journal of the American Society of Hematology 137 (3), 374-386, 2021
强制性开放获取政策： US National Institutes of Health
Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL‐2 inhibitor, in patients with non‐Hodgkin lymphoma
SK Agarwal, AH Salem, AV Danilov, B Hu, S Puvvada, M Gutierrez, ...
British journal of clinical pharmacology 83 (4), 846-854, 2017
强制性开放获取政策： US National Institutes of Health
DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance
AV Danilov, D Neupane, AS Nagaraja, EV Feofanova, LA Humphries, ...
PloS one 6 (10), e26815, 2011
强制性开放获取政策： US National Institutes of Health
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib
MJ Gordon, M Churnetski, H Alqahtani, X Rivera, A Kittai, SM Amrock, ...
Cancer 124 (15), 3192-3200, 2018
强制性开放获取政策： Lymphoma Research Foundation, USA
Burkitt lymphoma international prognostic index
AJ Olszewski, LH Jakobsen, GP Collins, K Cwynarski, V Bachanova, ...
Journal of clinical oncology 39 (10), 1129-1138, 2021
强制性开放获取政策： US National Institutes of Health
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma
S Yi, Y Yan, M Jin, S Bhattacharya, Y Wang, Y Wu, L Yang, E Gine, G Clot, ...
The Journal of clinical investigation 132 (3), 2022
强制性开放获取政策： US National Institutes of Health, 国家自然科学基金委员会, Government of …
Targeted therapy in chronic lymphocytic leukemia: past, present, and future
AV Danilov
Clinical therapeutics 35 (9), 1258-1270, 2013
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定